Counting alleles to predict recurrence of early-stage colorectal cancers

Wei Zhou, Steven N. Goodman, Gennaro Galizia, Eva Lieto, Francesca Ferraraccio, Carlo Pignatelli, Colin A. Purdie, Juan Piris, Robert Morris, David J. Harrison, Philip B. Paty, Al Culliford, Katharine E. Romans, Elizabeth A Montgomery, Michael A. Choti, Kenneth W Kinzler, Bert Vogelstein

Research output: Contribution to journalArticle

Abstract

Background: Chromosome imbalances occur in many cancers and represent important biological properties of tumours. However, measurements of such imbalances are difficult. We used a new, quantitative approach to investigate the prognostic value of chromosome imbalances in early-stage colorectal cancers. Methods: We studied 180 patients with no evidence of lymph-node or distant metastases at the time of surgery. DNA from paraffin-embedded tumours was tested for imbalances of chromosome 8p and 18q by digital SNP (single-nucleotide polymorphism) - a technique in which each allele in a sample is directly counted. Surviving patients had median follow-up of 68 months, and disease recurrence was used as the clinical endpoint. Findings: Tumours were divided into three groups: "L" tumours (n = 93) had allelic imbalances of chromosomes 8p and 18q, "L/R" tumours (n = 60) had allelic imbalances of either chromosome 8p or 18q but not both, and "R" tumours (n = 27) retained allelic balance for both chromosomes. 5-year disease-free survival was 100% (95% CI 80-100) for patients with R tumours, 74% (61-87) for patients with L/R tumours, and 58% (47-69) for those with L tumours. These differences were significant (p <0.0001) and were independent of other variables - eg, Duke's stage A tumours of class L were much more likely to recur than Duke's stage B tumours of class R (p = 0.002). Interpretation: In patients without metastasis, allelic imbalance is a better predictor of prognosis than histopathological stage.

Original languageEnglish (US)
Pages (from-to)219-225
Number of pages7
JournalThe Lancet
Volume359
Issue number9302
DOIs
StatePublished - Jan 19 2002

Fingerprint

Colorectal Neoplasms
Alleles
Recurrence
Neoplasms
Chromosomes
Allelic Imbalance
Neoplasm Metastasis
Paraffin
Disease-Free Survival
Single Nucleotide Polymorphism
Lymph Nodes
DNA

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zhou, W., Goodman, S. N., Galizia, G., Lieto, E., Ferraraccio, F., Pignatelli, C., ... Vogelstein, B. (2002). Counting alleles to predict recurrence of early-stage colorectal cancers. The Lancet, 359(9302), 219-225. https://doi.org/10.1016/S0140-6736(02)07448-2

Counting alleles to predict recurrence of early-stage colorectal cancers. / Zhou, Wei; Goodman, Steven N.; Galizia, Gennaro; Lieto, Eva; Ferraraccio, Francesca; Pignatelli, Carlo; Purdie, Colin A.; Piris, Juan; Morris, Robert; Harrison, David J.; Paty, Philip B.; Culliford, Al; Romans, Katharine E.; Montgomery, Elizabeth A; Choti, Michael A.; Kinzler, Kenneth W; Vogelstein, Bert.

In: The Lancet, Vol. 359, No. 9302, 19.01.2002, p. 219-225.

Research output: Contribution to journalArticle

Zhou, W, Goodman, SN, Galizia, G, Lieto, E, Ferraraccio, F, Pignatelli, C, Purdie, CA, Piris, J, Morris, R, Harrison, DJ, Paty, PB, Culliford, A, Romans, KE, Montgomery, EA, Choti, MA, Kinzler, KW & Vogelstein, B 2002, 'Counting alleles to predict recurrence of early-stage colorectal cancers', The Lancet, vol. 359, no. 9302, pp. 219-225. https://doi.org/10.1016/S0140-6736(02)07448-2
Zhou W, Goodman SN, Galizia G, Lieto E, Ferraraccio F, Pignatelli C et al. Counting alleles to predict recurrence of early-stage colorectal cancers. The Lancet. 2002 Jan 19;359(9302):219-225. https://doi.org/10.1016/S0140-6736(02)07448-2
Zhou, Wei ; Goodman, Steven N. ; Galizia, Gennaro ; Lieto, Eva ; Ferraraccio, Francesca ; Pignatelli, Carlo ; Purdie, Colin A. ; Piris, Juan ; Morris, Robert ; Harrison, David J. ; Paty, Philip B. ; Culliford, Al ; Romans, Katharine E. ; Montgomery, Elizabeth A ; Choti, Michael A. ; Kinzler, Kenneth W ; Vogelstein, Bert. / Counting alleles to predict recurrence of early-stage colorectal cancers. In: The Lancet. 2002 ; Vol. 359, No. 9302. pp. 219-225.
@article{06848eb738c748b7a2f4134ad4ba863e,
title = "Counting alleles to predict recurrence of early-stage colorectal cancers",
abstract = "Background: Chromosome imbalances occur in many cancers and represent important biological properties of tumours. However, measurements of such imbalances are difficult. We used a new, quantitative approach to investigate the prognostic value of chromosome imbalances in early-stage colorectal cancers. Methods: We studied 180 patients with no evidence of lymph-node or distant metastases at the time of surgery. DNA from paraffin-embedded tumours was tested for imbalances of chromosome 8p and 18q by digital SNP (single-nucleotide polymorphism) - a technique in which each allele in a sample is directly counted. Surviving patients had median follow-up of 68 months, and disease recurrence was used as the clinical endpoint. Findings: Tumours were divided into three groups: {"}L{"} tumours (n = 93) had allelic imbalances of chromosomes 8p and 18q, {"}L/R{"} tumours (n = 60) had allelic imbalances of either chromosome 8p or 18q but not both, and {"}R{"} tumours (n = 27) retained allelic balance for both chromosomes. 5-year disease-free survival was 100{\%} (95{\%} CI 80-100) for patients with R tumours, 74{\%} (61-87) for patients with L/R tumours, and 58{\%} (47-69) for those with L tumours. These differences were significant (p <0.0001) and were independent of other variables - eg, Duke's stage A tumours of class L were much more likely to recur than Duke's stage B tumours of class R (p = 0.002). Interpretation: In patients without metastasis, allelic imbalance is a better predictor of prognosis than histopathological stage.",
author = "Wei Zhou and Goodman, {Steven N.} and Gennaro Galizia and Eva Lieto and Francesca Ferraraccio and Carlo Pignatelli and Purdie, {Colin A.} and Juan Piris and Robert Morris and Harrison, {David J.} and Paty, {Philip B.} and Al Culliford and Romans, {Katharine E.} and Montgomery, {Elizabeth A} and Choti, {Michael A.} and Kinzler, {Kenneth W} and Bert Vogelstein",
year = "2002",
month = "1",
day = "19",
doi = "10.1016/S0140-6736(02)07448-2",
language = "English (US)",
volume = "359",
pages = "219--225",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9302",

}

TY - JOUR

T1 - Counting alleles to predict recurrence of early-stage colorectal cancers

AU - Zhou, Wei

AU - Goodman, Steven N.

AU - Galizia, Gennaro

AU - Lieto, Eva

AU - Ferraraccio, Francesca

AU - Pignatelli, Carlo

AU - Purdie, Colin A.

AU - Piris, Juan

AU - Morris, Robert

AU - Harrison, David J.

AU - Paty, Philip B.

AU - Culliford, Al

AU - Romans, Katharine E.

AU - Montgomery, Elizabeth A

AU - Choti, Michael A.

AU - Kinzler, Kenneth W

AU - Vogelstein, Bert

PY - 2002/1/19

Y1 - 2002/1/19

N2 - Background: Chromosome imbalances occur in many cancers and represent important biological properties of tumours. However, measurements of such imbalances are difficult. We used a new, quantitative approach to investigate the prognostic value of chromosome imbalances in early-stage colorectal cancers. Methods: We studied 180 patients with no evidence of lymph-node or distant metastases at the time of surgery. DNA from paraffin-embedded tumours was tested for imbalances of chromosome 8p and 18q by digital SNP (single-nucleotide polymorphism) - a technique in which each allele in a sample is directly counted. Surviving patients had median follow-up of 68 months, and disease recurrence was used as the clinical endpoint. Findings: Tumours were divided into three groups: "L" tumours (n = 93) had allelic imbalances of chromosomes 8p and 18q, "L/R" tumours (n = 60) had allelic imbalances of either chromosome 8p or 18q but not both, and "R" tumours (n = 27) retained allelic balance for both chromosomes. 5-year disease-free survival was 100% (95% CI 80-100) for patients with R tumours, 74% (61-87) for patients with L/R tumours, and 58% (47-69) for those with L tumours. These differences were significant (p <0.0001) and were independent of other variables - eg, Duke's stage A tumours of class L were much more likely to recur than Duke's stage B tumours of class R (p = 0.002). Interpretation: In patients without metastasis, allelic imbalance is a better predictor of prognosis than histopathological stage.

AB - Background: Chromosome imbalances occur in many cancers and represent important biological properties of tumours. However, measurements of such imbalances are difficult. We used a new, quantitative approach to investigate the prognostic value of chromosome imbalances in early-stage colorectal cancers. Methods: We studied 180 patients with no evidence of lymph-node or distant metastases at the time of surgery. DNA from paraffin-embedded tumours was tested for imbalances of chromosome 8p and 18q by digital SNP (single-nucleotide polymorphism) - a technique in which each allele in a sample is directly counted. Surviving patients had median follow-up of 68 months, and disease recurrence was used as the clinical endpoint. Findings: Tumours were divided into three groups: "L" tumours (n = 93) had allelic imbalances of chromosomes 8p and 18q, "L/R" tumours (n = 60) had allelic imbalances of either chromosome 8p or 18q but not both, and "R" tumours (n = 27) retained allelic balance for both chromosomes. 5-year disease-free survival was 100% (95% CI 80-100) for patients with R tumours, 74% (61-87) for patients with L/R tumours, and 58% (47-69) for those with L tumours. These differences were significant (p <0.0001) and were independent of other variables - eg, Duke's stage A tumours of class L were much more likely to recur than Duke's stage B tumours of class R (p = 0.002). Interpretation: In patients without metastasis, allelic imbalance is a better predictor of prognosis than histopathological stage.

UR - http://www.scopus.com/inward/record.url?scp=0037132902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037132902&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(02)07448-2

DO - 10.1016/S0140-6736(02)07448-2

M3 - Article

C2 - 11812558

AN - SCOPUS:0037132902

VL - 359

SP - 219

EP - 225

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9302

ER -